Local Coverage Article Response to Comments

Response to Comments: Intravenous Immune Globulin (IVIG) L35893


Expand All | Collapse All

Contractor Information

Article Information

General Information

Article ID
Article Title
Response to Comments: Intravenous Immune Globulin (IVIG) L35893
Article Type
Response to Comments
Original Effective Date
Retirement Date
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text
The following are comments received during the comment period for draft LCD DL35893 Intravenous Immune Globulin (IVIG). The policy has been released to its final version with any updates made as indicated in the comment section.

Response To Comments

1Please consider adding coverage for multiple myeloma.CGS will add the following paragraph for multiple myeloma to the final version of the IVIG policy. Multiple Myeloma IVIG is indicated in patients with multiple myeloma to reduce the incidence of recurrent bacterial infection when the patient is in the plateau phase of the disease and there is evidence of immunodeficiency as indicated by a serum IgG level <600mg/dl and a history of one documented, serious bacterial infection requiring IV antibiotic therapy in the previous six months or two or more such infections in the previous one year. IVIG will also be considered medically necessary when there has been a failure to mount an appropriate IgG humoral response to pneumococcal vaccine. IVIG therapy is not considered medically reasonable and necessary during primary induction chemotherapy or during a relapse of the disease.

Associated Documents

Related Local Coverage Documents
Related National Coverage Documents
Public Versions
Updated On Effective Dates Status
03/31/2015 10/01/2015 - N/A Currently in Effect You are here